Current treatments of DN mainly focus on anti-RAS therapy by blocking Ang II, ACE, and AT1R, but only few studies have been performed to understand the local regulation of each RAS component by high-glucose stimulation, and the potential relations with inflammation are still unclear. The gene discussed is AGT; the disease is liver dysplastic nodule.